Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 8OTHER 4OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 3Colorectal Neoplasms 2

Interventions

Irinotecan 11Oxaliplatin 8Cetuximab 7Fluorouracil 6Leucovorin 5Bevacizumab 5Standard of Care 4S 1 (combination) 4Capecitabine 4trifluridine tipiracil drug combination 2tislelizumab 2apatinib 2Propranolol 2Preoperative Exercise 2Panitumumab 2Levoleucovorin 2Folfox protocol 2Etodolac 2Endoscopic Mucosal Resection 2Drug Therapy 2Chemotherapy, Adjuvant 2trebananib 1regorafenib 1envafolimab 1Trifluridine 1Thalidomide 1Surveys and Questionnaires 1Occult Blood 1Neoadjuvant Therapy 1Moxibustion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Colorectal Neoplasms × Levoleucovorin × Clear all
NCT05839470 2023-11-15

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Fujian Cancer Hospital

Phase 2 Unknown
20 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT03222089 2018-03-27

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

Fujian Cancer Hospital

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡